Month: September 2021

HiPay: Availability of the 2021 first half financial report Paris, September 14, 2021: HiPay (ISIN code FR0012821916 – HIPAY), the fintech specialized in Omnichannel payment solutions, announces the availability of its legal document. The french financial report for the first half of 2021 can be consulted in the Investors section of the company’s website (https://hipay.com/en/investors). Next financial communication: October 28,  2021 – Q3 2021 resultsAbout HiPay HiPay is a global payment provider. By harnessing the power of payment data, we participate in our merchants’ growth by bringing them a 360° vision of their activities. More information on hipay.com and find us on LinkedIn. HiPay Group is listed on the Euronext Paris Compartment C (ISIN code: FR0012821916 – Mnemo: HIPAY).  Press Contact Investors RelationsJawad...

H1 2021 resultsHiPay confirms its profitable growth trajectory. Strong increase in payment volume (+27%, €3.2 billion).Revenues[1] up by +23% vs. H1 2020, driven by higher payment volume (+27% vs. H1 2020 and +82% vs. H1 2019). Operating profit, which has been growing steadily is now close to break-even, at € -0.4 million. HiPay’s financing capacity stands at €8.6 million as of 30 June 2021.  IDMidCaps initiated coverage of HiPay[2]  with a “buy” recommendation in September.[1] Unaudited data [2] Coverage commissioned by the issuer, available on the company’s website https://hipay.com/fr/investisseursAbout HiPay HiPay is a global payment provider. By harnessing the power of payment data, we participate in our merchants’ growth by bringing them a 360° vision of their activities. More information on hipay.com...

GPOX launches social media content campaign$GPOX – GPO Plus+ Announces Filing of 2021 Annual Report on Form 10-K$GPOX – FORM 10-K, April 30, 2021LAS VEGAS, NV, Sept. 13, 2021 (GLOBE NEWSWIRE) — GPO Plus, Inc. (OTCQB: GPOX), a publicly traded company of diversified industry-specific Group Purchasing Organizations (GPOs), today announced the Company has filed with the Securities and Exchange Commission (“SEC”) its Annual Report on Form 10-K for its fiscal year ended April 30, 2021 (the “2021 Annual Report”) and also announced the launch of its social media content campaign. Today’s announcement follows the Company’s recent press release that it has exited stealth mode and is starting to share the GPOX story with the investment community. Additionally, GPOX started publishing content on select social...

SHANGHAI, China and REDWOOD CITY, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc. (Nasdaq: CHRS) announced the presentation today of positive interim results from the pivotal study “CHOICE-01” (NCT03856411), a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab plus chemotherapy as the first-line treatment of advanced squamous or non-squamous non-small cell lung cancer (NSCLC) without driver mutations. The interim analysis met the primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression free survival (PFS) per RECIST v1.1 compared to chemotherapy alone.  The interim results were summarized on September 13 in a presentation by...

MELBOURNE, Australia and INDIANAPOLIS, Sept. 13, 2021 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) has today welcomed the updated National Comprehensive Cancer Network® (NCCN) Guidelines® for prostate cancer,1 which includes prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging modalities, including Ga-68 PSMA-11. Telix’s New Drug Application (NDA) for its investigational imaging product Illuccix® (Kit for the preparation of 68Ga-PSMA-11 injection) is in the late stages of review by the United States Food and Drug Administration. The NCCN Guidelines® are a recognised standard for clinical direction and policy in cancer care and are used widely by clinicians and payors. The NCCN panel has recognised the increased sensitivity and specificity of PSMA-PET tracers, compared...

REDWOOD CITY, Calif. and SHANGHAI, China , Sept. 13, 2021 (GLOBE NEWSWIRE) — Coherus Biosciences, Inc. (Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced the presentation today of positive interim results from the pivotal study “CHOICE-01” (NCT03856411), a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab plus chemotherapy as first-line treatment of advanced squamous or non-squamous non-small cell lung cancer (NSCLC) without driver mutations. The interim analysis met the primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression free survival (PFS) per RECIST v1.1 compared to chemotherapy alone.  The interim results were summarized on September 13 in a presentation by Professor Jie...

VANCOUVER, British Columbia, Sept. 13, 2021 (GLOBE NEWSWIRE) — Sunniva Inc. (“Sunniva”, the “Company”) (CSE:SNN) (OTC Pink Sheets:SNNVF) announces an update regarding work on the audits of the Company’s financial statements for the years ended December 31, 2019 and 2020.     After implementation of its Amended and Consolidated Plan of Compromise and Arrangement and its release and discharge from its CCAA proceedings, the Company engaged MNP LLP (“MNP”), its historical auditor, to conduct financial statement audits for the years ended December 31, 2019 and 2020. Since the engagement of MNP, both the Company and MNP have done a significant amount of work on the 2019 audit and started work on the 2020 audit. During the course of this audit work, MNP has come to the conclusion that it will not be able to obtain audit level comfort...

MONTREAL, Sept. 13, 2021 (GLOBE NEWSWIRE) — Imperial Mining Group Ltd. (“Imperial” or the “Corporation”) (TSX VENTURE: IPG) is pleased to announce that it closed the first tranche of a non-brokered private placement (the “Offering”) of 5,460,000 units (each, a “Unit”) at a price of $0.15 per Unit, for an aggregate gross proceeds $819,000. The Offering is set for an aggregate gross proceeds of a maximum of $1,500,000. Each Unit is comprised of one (1) common share (each a “Share”) and one (1) a Share purchase warrant (each a “Warrant”), with each Warrant entitling the holder to acquire one (1) additional Share of the Corporation at a price of $0.20 over a period of twenty-four (24) months from the closing date. The Corporation will use the proceeds of the Offering to complete exploration on the Corporation’s Crater Lake TG Zone...